VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Oramed Pharmaceuticals Executive Compensation (FY25)

ORMP · Executive and director compensation, fiscal 2022 to 2025
Latest say-on-pay support
=
August 1, 2024
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Oramed Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 25, 2026Latest filing (DEF 14A): August 3, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Oramed Pharmaceuticals brief$1,500Get the executive brief
Velarion Intel, one year, every company
117 figures on this page: 112 cited to the filing that reported them, 5 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.
What was Oramed Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 90.0% of votes cast for or against in favor at the meeting held August 1, 2024 for fiscal 2023.
Which companies are in Oramed Pharmaceuticals' peer group?
The disclosed peer group includes ALX Oncology Holdings Inc., AN2 Therapeutics, Inc., Anavex Life Sciences Corp., Atossa Therapeutics Inc. and aTyr Pharma, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nadav Kidron
President, Chief Executive Officer and Chairman (6)
◇◇◇◇——◇◇
Miriam Kidron
Chief Scientific Officer and director (7)
◇◇◇◇——◇◇
David Silberman
Chief Financial Officer (8)
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nadav Kidron
President, Chief Executive Officer and Chairman
◇◇◇———◇◇
Miriam Kidron
Chief Scientific Officer and director
◇◇◇———◇◇
Joshua Hexter
Chief Operating & Business Officer
◇◇◇———◇◇
David Silberman
Chief Financial Officer (8)
◇◇◇———◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nadav Kidron
President, Chief Executive Officer and Chairman
◇◇◇———◇◇
Miriam Kidron
Chief Scientific Officer and director (5)
◇◇◇———◇◇
Joshua Hexter
Chief Operating & Business Officer
◇◇◇———◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nadav Kidron
President, Chief Executive Officer and Chairman
◇◇◇———◇— not reconciled
Miriam Kidron
Chief Scientific Officer and director (5)
◇◇◇———◇◇
Joshua Hexter
Chief Operating and Business Officer
◇◇◇———◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Joshua HexterOption◇—◇9/11/29
Option◇—◇1/3/32
Nadav KidronOption◇—◇1/3/32
Miriam KidronOption◇—◇1/3/32
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dr. Daniel Aghion
◇◇————◇
Yehuda Reznick
◇◇————◇
Dr. Arie Mayer
◇◇————◇
Benjamin Shapiro
◇◇————◇
Leonard Sank
◇◇————◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee member◇
Compensation committee member◇
Nominating and governance member◇
Board meeting fee◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • ALX Oncology Holdings Inc. ALXO
  • AN2 Therapeutics, Inc. ANTX
  • Anavex Life Sciences Corp. AVXL
  • Atossa Therapeutics Inc. symbol not shown
  • aTyr Pharma, Inc. ATYR
  • Chimerix, Inc. CMRX
  • Compugen Ltd. symbol not shown
  • Fulcrum Therapeutics, Inc. FULC
  • Immunic, Inc. symbol not shown
  • Marinus Pharmaceuticals, Inc. MRNS
  • MediciNova, Inc. symbol not shown
  • Relmada Therapeutics, Inc. RLMD
  • Rezolute, Inc. RZLT
  • Vistagen Therapeutics, Inc. symbol not shown
  • vTv Therapeutics Inc. symbol not shown
  • Zevra Therapeutics, Inc. ZVRA

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2023August 1, 2024=◇◇◇
2021June 30, 2022=◇◇◇
2019August 3, 2020=◇◇◇
2017August 28, 2018=◇◇◇
2015August 30, 2016=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Nadav Kidron (President, Chief Executive Officer and Chairman), FY2025 total compensation $4,774,460 (base salary $619,529) [exec_comp, SEC accession 0001213900-26-084609, filed 2026-08-03]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Oramed Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Oramed Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Oramed Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Oramed Pharmaceuticals' disclosed peer group is defensible, who names Oramed Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
117 figures on this page: 112 cited to the filing that reported them, 5 calculated from figures it prints.
112 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001213900-26-084609
    DIRECTOR COMPENSATION
  2. 0001213900-25-064755
  3. 0001213900-24-064732
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  4. 0001213900-24-054007
  5. 0001213900-22-036294
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  6. 0001213900-20-020031
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  7. 0001213900-18-011939
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  8. 0001213900-16-016514
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Oramed Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ORMP (accessed 2026).
Short form: data: Velarion

The Oramed Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Oramed Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Oramed Pharmaceuticals discloses

The companies named in ORMP's own disclosed peer group.

ALX Oncology Holdings Inc.AN2 Therapeutics, Inc.Anavex Life Sciences Corp.aTyr Pharma, Inc.Chimerix, Inc.Fulcrum Therapeutics, Inc.Marinus Pharmaceuticals, Inc.Relmada Therapeutics, Inc.Rezolute, Inc.Zevra Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy